Dovato is a once-daily prescription pill used to treat HIV-1 in adults. It combines two antiretroviral drugs into a single tablet, making it one of the simplest HIV treatment options available. What sets Dovato apart from most HIV regimens is that it contains only two active ingredients instead of the traditional three, reducing the overall medication exposure while still keeping the virus fully suppressed.
Who Dovato Is Approved For
The FDA approved Dovato for two groups of people. The first is adults who have never taken HIV treatment before. The second is people already on a different HIV regimen who have achieved viral suppression (fewer than 50 copies of the virus per milliliter of blood) and want to simplify their treatment. U.S. federal treatment guidelines give Dovato their strongest recommendation rating for first-line therapy, with a few exceptions: it’s not the best choice for people with very high viral loads above 500,000 copies per milliliter, those co-infected with hepatitis B, or those starting treatment before resistance test results come back.
Dovato has also been approved for adolescents aged 12 and older who weigh at least 55 pounds, though it’s most commonly prescribed to adults.
How Dovato Works
Dovato contains two drugs that block HIV replication at different points in the virus’s life cycle. The first, dolutegravir, is an integrase inhibitor. It prevents HIV from inserting its genetic material into your cells’ DNA, which is a critical step the virus needs to reproduce. The second, lamivudine, works earlier in the process by mimicking one of the building blocks the virus uses to copy itself. When the virus mistakenly grabs lamivudine instead of the real building block, the copying process stalls and the new viral strand can’t be completed.
By attacking HIV at two separate stages, the combination keeps viral levels undetectable in most people, even without a third drug.
How Well It Works
The major clinical trials behind Dovato, called GEMINI-1 and GEMINI-2, compared the two-drug regimen against a standard three-drug regimen in people starting HIV treatment for the first time. At 48 weeks, about 85% of participants on Dovato who started with very high viral loads (500,000 copies or more) achieved undetectable levels. That was comparable to the three-drug group, where 80% reached the same goal. Results held up over longer follow-up as well.
For people switching from an existing regimen, a trial called TANGO looked at what happened when patients already suppressed on a three-drug combination moved to Dovato. At 48 weeks, 93% of those who switched maintained viral suppression, exactly matching the 93% who stayed on their original three-drug regimen. In other words, dropping from three drugs to two didn’t compromise viral control.
The Two-Drug Advantage
Traditional HIV treatment uses three active drugs, often from two or three different drug classes. That approach has been the standard for decades because it provides a high barrier to resistance. Dovato was designed to test whether fewer drugs could do the same job while lowering the overall burden on your body.
One practical benefit is reduced long-term medication exposure. Fewer active ingredients means fewer potential drug interactions and, in some cases, a more favorable side effect profile. Weight gain, for example, is a common concern with many modern HIV regimens. In the PASO-DOBLE study comparing Dovato against a popular three-drug combination, participants on Dovato were significantly less likely to gain more than 5% of their body weight. At 96 weeks, 24% of the Dovato group crossed that threshold compared to nearly 38% on the three-drug alternative. Other studies have shown minimal weight changes on Dovato, with one reporting a mean gain of only about 0.25 kilograms over 48 weeks.
Who Should Not Take Dovato
Dovato is not appropriate for everyone with HIV. People co-infected with hepatitis B need a different regimen because lamivudine also has activity against that virus. Stopping lamivudine in someone with hepatitis B can trigger a dangerous flare of liver inflammation, so the treatment plan needs to account for both infections from the start.
It’s also not suitable for people whose virus has developed resistance to either of its two components. If previous treatment has allowed the virus to develop mutations that reduce the effectiveness of lamivudine or dolutegravir, Dovato won’t provide reliable suppression. This is why it’s specifically approved for people with no history of treatment failure and no known resistance mutations to either drug. Resistance testing before starting treatment is standard practice.
What Taking Dovato Looks Like
Dovato is a single tablet taken once a day, with or without food. There’s no complicated dosing schedule or meal timing to worry about. For many people, this simplicity is part of the appeal. HIV treatment is lifelong, and a regimen that’s easy to stick with day after day helps maintain the consistent drug levels needed to keep the virus suppressed.
The most commonly reported side effects in clinical trials include headache, nausea, diarrhea, difficulty sleeping, and fatigue. Most of these are mild and tend to improve within the first few weeks. Dolutegravir, one of the two components, can cause a small increase in a blood marker called creatinine that might look like a kidney issue on lab tests but doesn’t actually reflect kidney damage. Your provider will be aware of this and interpret your lab work accordingly.
How Dovato Fits Into Current Treatment
U.S. Department of Health and Human Services guidelines list Dovato as a recommended first-line option for most adults starting HIV treatment, giving it their highest evidence rating based on data from randomized controlled trials. It sits alongside several three-drug regimens as a preferred choice, not a second-tier alternative.
For people already on a suppressive regimen who are interested in simplifying, Dovato is one of the more studied switch options. The key requirements are stable viral suppression, no history of treatment failure, and no hepatitis B co-infection. If those boxes are checked, the switch can reduce pill burden and long-term drug exposure without sacrificing viral control.